vs

Side-by-side financial comparison of BayFirst Financial Corp. (BAFN) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.2M, roughly 1.1× BayFirst Financial Corp.). BayFirst Financial Corp. runs the higher net margin — -22.1% vs -1398.3%, a 1376.3% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 4.7%). BayFirst Financial Corp. produced more free cash flow last quarter ($285.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -30.4%).

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

BAFN vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.2M
BAFN
Growing faster (revenue YoY)
RNA
RNA
+429.3% gap
RNA
434.0%
4.7%
BAFN
Higher net margin
BAFN
BAFN
1376.3% more per $
BAFN
-22.1%
-1398.3%
RNA
More free cash flow
BAFN
BAFN
$441.9M more FCF
BAFN
$285.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-30.4%
BAFN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BAFN
BAFN
RNA
RNA
Revenue
$11.2M
$12.5M
Net Profit
$-2.5M
$-174.4M
Gross Margin
Operating Margin
-25.3%
-1513.5%
Net Margin
-22.1%
-1398.3%
Revenue YoY
4.7%
434.0%
Net Profit YoY
-125.2%
-117.0%
EPS (diluted)
$-0.71
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAFN
BAFN
RNA
RNA
Q4 25
$11.2M
Q3 25
$10.2M
$12.5M
Q2 25
$23.1M
$3.8M
Q1 25
$19.8M
$1.6M
Q4 24
$32.9M
$3.0M
Q3 24
$21.7M
$2.3M
Q2 24
$20.8M
$2.0M
Q1 24
$23.0M
$3.5M
Net Profit
BAFN
BAFN
RNA
RNA
Q4 25
$-2.5M
Q3 25
$-18.9M
$-174.4M
Q2 25
$-1.2M
$-157.3M
Q1 25
$-335.0K
$-115.8M
Q4 24
$9.8M
$-102.3M
Q3 24
$1.1M
$-80.4M
Q2 24
$866.0K
$-70.8M
Q1 24
$824.0K
$-68.9M
Operating Margin
BAFN
BAFN
RNA
RNA
Q4 25
-25.3%
Q3 25
-253.0%
-1513.5%
Q2 25
-7.1%
-4448.7%
Q1 25
-2.3%
-8360.9%
Q4 24
-4069.6%
Q3 24
7.1%
-4200.9%
Q2 24
5.9%
-4040.4%
Q1 24
5.1%
-2178.6%
Net Margin
BAFN
BAFN
RNA
RNA
Q4 25
-22.1%
Q3 25
-184.7%
-1398.3%
Q2 25
-5.3%
-4089.3%
Q1 25
-1.7%
-7360.0%
Q4 24
91.8%
-3439.5%
Q3 24
5.2%
-3441.7%
Q2 24
4.2%
-3461.8%
Q1 24
3.6%
-1943.4%
EPS (diluted)
BAFN
BAFN
RNA
RNA
Q4 25
$-0.71
Q3 25
$-4.66
$-1.27
Q2 25
$-0.39
$-1.21
Q1 25
$-0.17
$-0.90
Q4 24
$2.21
$-0.80
Q3 24
$0.18
$-0.65
Q2 24
$0.12
$-0.65
Q1 24
$0.11
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAFN
BAFN
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$207.0M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.6M
$1.9B
Total Assets
$1.3B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAFN
BAFN
RNA
RNA
Q4 25
$207.0M
Q3 25
$118.5M
$350.2M
Q2 25
$77.3M
$243.9M
Q1 25
$63.2M
$254.2M
Q4 24
$77.8M
$219.9M
Q3 24
$64.4M
$370.2M
Q2 24
$60.8M
$575.8M
Q1 24
$57.5M
$471.4M
Stockholders' Equity
BAFN
BAFN
RNA
RNA
Q4 25
$87.6M
Q3 25
$89.7M
$1.9B
Q2 25
$108.2M
$1.2B
Q1 25
$110.1M
$1.3B
Q4 24
$110.9M
$1.4B
Q3 24
$102.3M
$1.5B
Q2 24
$101.0M
$1.2B
Q1 24
$100.6M
$830.9M
Total Assets
BAFN
BAFN
RNA
RNA
Q4 25
$1.3B
Q3 25
$1.3B
$2.1B
Q2 25
$1.3B
$1.4B
Q1 25
$1.3B
$1.5B
Q4 24
$1.3B
$1.6B
Q3 24
$1.2B
$1.6B
Q2 24
$1.2B
$1.3B
Q1 24
$1.1B
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAFN
BAFN
RNA
RNA
Operating Cash FlowLast quarter
$285.3M
$-156.2M
Free Cash FlowOCF − Capex
$285.0M
$-156.9M
FCF MarginFCF / Revenue
2554.2%
-1257.6%
Capex IntensityCapex / Revenue
2.7%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$469.5M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAFN
BAFN
RNA
RNA
Q4 25
$285.3M
Q3 25
$47.3M
$-156.2M
Q2 25
$63.3M
$-199.7M
Q1 25
$74.2M
$-124.8M
Q4 24
$390.5M
$-99.9M
Q3 24
$90.8M
$-65.6M
Q2 24
$78.8M
$-65.0M
Q1 24
$123.5M
$-70.4M
Free Cash Flow
BAFN
BAFN
RNA
RNA
Q4 25
$285.0M
Q3 25
$47.3M
$-156.9M
Q2 25
$63.1M
$-203.0M
Q1 25
$74.1M
$-128.6M
Q4 24
$388.8M
$-103.8M
Q3 24
$90.5M
$-67.3M
Q2 24
$78.4M
$-65.5M
Q1 24
$122.5M
$-71.3M
FCF Margin
BAFN
BAFN
RNA
RNA
Q4 25
2554.2%
Q3 25
462.2%
-1257.6%
Q2 25
272.7%
-5277.1%
Q1 25
375.1%
-8174.3%
Q4 24
1180.9%
-3491.0%
Q3 24
416.5%
-2881.8%
Q2 24
376.1%
-3204.6%
Q1 24
532.5%
-2012.3%
Capex Intensity
BAFN
BAFN
RNA
RNA
Q4 25
2.7%
Q3 25
0.1%
5.7%
Q2 25
0.8%
86.9%
Q1 25
0.4%
238.6%
Q4 24
5.1%
131.7%
Q3 24
1.5%
72.9%
Q2 24
1.9%
26.0%
Q1 24
4.4%
25.8%
Cash Conversion
BAFN
BAFN
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
39.95×
Q3 24
79.85×
Q2 24
90.94×
Q1 24
149.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons